Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel PIPAC with Second-Line Therapy for Gastric Cancer
NCT06675136Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Oct 2025
- Primary completion
- Jan 2029
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nab-paclitaxel in gastric cancer (GC), sponsored by City of Hope. Primary endpoint: Dose-limiting toxicity (DLT) up to 6 weeks. Started Oct 2025; status: recruiting.
02
Drugs
nab-paclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06675136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675136.